The bill enacts a new provision in the Uniform Controlled Dangerous Substances Law, specifically adding Tianeptine to Schedule I. This classification indicates that Tianeptine, along with its salts, isomers, or salts of isomers, is considered a controlled substance unless it is specifically exempted or contained within a pharmaceutical product approved by the United States Food and Drug Administration.

The new legal language inserted into the law outlines the criteria for substances to be classified under Schedule I, emphasizing that any material or compound containing Tianeptine will fall under this category. This legislative action aims to regulate the use and distribution of Tianeptine in Louisiana, reflecting concerns about its potential misuse and health risks.